drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous CD19-directed CAR T-cell therapy; patient T cells engineered to express a CAR targeting CD19, administered as a single IV dose to deplete CD19+ B-lineage cells and reset humoral immunity.
nci_thesaurus_concept_id
C203740
nci_thesaurus_preferred_term
Autologous Anti-CD19 CAR-T Cells CABA-201
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-lymphocyte antigen CD19, coupled to a costimulatory domain of 4-1BB (CD137), with potential immunomodulatory activity. Upon administration, autologous anti-CD19 CAR-T cells CABA-201 target and bind to CD19-expressing B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing B-cells. CD19, a B-cell-specific cell surface antigen that plays an important role in B-cell activation, is overexpressed in some autoimmune diseases.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti-CD19 CAR with a 4-1BB costimulatory domain bind and kill CD19+ B-lineage cells (including B cells and plasmablasts), producing deep B-cell depletion and resetting humoral immunity.
drug_name
CABA-201
nct_id_drug_ref
NCT06328777